TREM2 is a potential therapeutic target due to its neuroprotective role in early AD, mitigating neuroinflammation, cognitive impairment, and M1 microglia polarization via the PI3K/AKT/FoxO3a pathway in AD models (Wang Y. et al., 2020). The gene discussed is AKT1; the disease is Alzheimer disease.